RAJAF
Cordyceps Sunshine Biotech Holdings Co., Ltd. engages in the cultivation and sale of Chinese rare medicinal herb, taiwanofungus raw material, and finished products in China. The company offers Taiwanofungus Oral pill, a pill form dietary supplement; Taiwanofungus Double A Oral shot, TAIWANOFUNGUS x SALVIA MILTIORRHIZA ORAL Shot, and Collagen Max Drink, a liquid form dietary supplement; and Barbie… Read more
RAJAF (RAJAF) - Net Assets
Latest net assets as of December 2023: $-151.80K USD
Based on the latest financial reports, RAJAF (RAJAF) has net assets worth $-151.80K USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.35 Million) and total liabilities ($3.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-151.80K |
| % of Total Assets | -4.53% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
RAJAF - Net Assets Trend (2020–2024)
This chart illustrates how RAJAF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for RAJAF (2020–2024)
The table below shows the annual net assets of RAJAF from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-375.54K | -147.40% |
| 2023-12-31 | $-151.80K | +84.04% |
| 2022-12-31 | $-951.33K | -244.92% |
| 2021-12-31 | $-275.81K | -2052.77% |
| 2020-12-31 | $-12.81K | -- |
Equity Component Analysis
This analysis shows how different components contribute to RAJAF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 68574800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $323.68K | % |
| Total Equity | $-375.54K | 100.00% |
RAJAF Competitors by Market Cap
The table below lists competitors of RAJAF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Smart Eye AB
ST:SEYE
|
$168.51 Million |
|
Tropicana Corporation Bhd
KLSE:5401
|
$168.53 Million |
|
Ricardo plc
F:RIR
|
$168.54 Million |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
$168.57 Million |
|
CviLux Corp
TW:8103
|
$168.42 Million |
|
Adimmune Corp
TW:4142
|
$168.40 Million |
|
Lotus Resources Ltd
AU:LOT
|
$168.39 Million |
|
Klaveness Combination Carriers ASA
OL:KCC
|
$168.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RAJAF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -151,796 to -375,543, a change of -223,747.
- Net loss of 226,258 reduced equity.
- Other factors increased equity by 2,511.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-226.26K | -60.25% |
| Other Changes | $2.51K | +0.67% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares RAJAF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $9.22 | x |
| 2021-12-31 | $0.00 | $9.22 | x |
| 2022-12-31 | $-0.01 | $9.22 | x |
| 2023-12-31 | $0.00 | $9.22 | x |
| 2024-12-31 | $0.00 | $9.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RAJAF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.05%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-463.42K |
| 2022 | 0.00% | -1350.92% | 0.03x | 0.00x | $-624.96K |
| 2023 | 0.00% | 85.16% | 0.26x | 0.00x | $766.79K |
| 2024 | 0.00% | -18.05% | 0.27x | 0.00x | $-188.70K |
Industry Comparison
This section compares RAJAF's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $5,681,533,529
- Average return on equity (ROE) among peers: 0.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RAJAF (RAJAF) | $-151.80K | 0.00% | N/A | $168.48 Million |
| Above Food Ingredients Inc. Common Stock (ABVE) | $30.90K | -3.31% | 7.66x | $18.76 Million |
| The a2 Milk Company Limited (ACOPF) | $7.27 Million | -30.19% | 0.14x | $3.91 Billion |
| Ayujoy Herbals Ltd (AJOY) | $22.20 Million | 29.29% | 0.00x | $95.71 |
| Alfa S.A.B. de C.V (ALFFF) | $53.35 Billion | 7.36% | 3.80x | $2.16 Billion |
| Amincor Inc (AMNCB) | $34.44 Million | -63.76% | 0.81x | $2.24K |
| Armanino Foods New (AMNF) | $21.40 Million | 30.30% | 0.33x | $72.33K |
| Amira Nature Foods Ltd (ANFIF) | $303.22 Million | 8.27% | 0.89x | $128.79 |
| AAK AB (publ.) (ARHUF) | $2.44 Billion | 12.85% | 2.63x | $5.07 Billion |
| Artisan Consumer Goods Inc (ARRT) | $-326.75K | 0.00% | 0.00x | $279.39K |
| ARYZTA AG (ARZTF) | $632.10 Million | 9.58% | 2.04x | $53.13 Million |